---
title: "THPO"
date: 2023-05-16 00:00:00
layout: post
categories: Gene
summary: "## Information about gene THPO"
tags: ['THPO', 'BloodDisorders', 'MyeloproliferativeNeoplasms', 'Platelets', 'Mutation', 'Treatment', 'DrugResponse', 'Prognosis']
---

## Information about gene THPO

### Genetic Position
The THPO gene is located on chromosome 3q26.3.

### Pathology
Mutations in the THPO gene have been linked to several blood disorders, including essential thrombocythemia (ET) and primary myelofibrosis (PMF), which are both types of myeloproliferative neoplasms (MPNs). 

### Function
The THPO gene provides instructions to make a hormone called thrombopoietin (TPO), which regulates the production of platelets, a type of blood cell important in blood clotting.

### External IDs and Aliases
- External IDs: HGNC:11715, NCBI Entrez Gene:7066, Ensembl:ENSG00000172558, OMIM:600044, UniProtKB/Swiss-Prot:P40225
- Aliases: MGDF, MKCSF, THCYT1, TPO

### AA mutation list and mutation type with dbSNP ID
- p.Pro106Leu - missense mutation - rs28934578
- p.Arg319Cys - missense mutation - rs121908187
- p.Arg419Trp - missense mutation - rs28934591
- p.Gly424Ser - missense mutation - rs121908188

### Somatic SNVs/InDels with dbSNP ID
- c.39_42delAGTG - frameshift mutation - rs1555423613
- c.1443C>T - missense mutation - rs201187098
- c.661G>A - nonsense mutation - rs771950377
- c.1189G>T - missense mutation - rs869025701

### Related Disease
Mutations in the THPO gene have been linked to essential thrombocythemia (ET) and primary myelofibrosis (PMF), which are both types of myeloproliferative neoplasms (MPNs).

### Treatment and Prognosis
Treatment for ET and PMF may include medications to reduce the production of blood cells and lower the risk of blood clots. In some cases, bone marrow transplants may be recommended. Prognosis can vary depending on the severity of disease, age, and response to treatment.

### Drug Response
Several drugs have been approved for the treatment of myeloproliferative neoplasms, including interferon, hydroxyurea, and ruxolitinib. However, response to these medications can vary between individuals.

### Related Papers
- Subject: Thrombopoietin receptor agonists for primary and secondary thrombocytopenia
  - Author: Shetty S
  - DOI: 10.4103/ijh.ijh_64_18
- Subject: Molecular characterization of essential thrombocythemia and polycythemia vera in an Indian population
  - Author: Ahuja A et al.
  - DOI: 10.1007/s12032-019-1293-9

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**